Concepedia

Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

Shomron Ben‐Horin, Miri Yavzori, Itai Benhar, Ella Fudim, Orit Picard, Bella Ungar, Soo Young Lee, Sung Hwan Kim, Rami Eliakim, Yehuda Chowers

Gut · 2015 · 174 citations · 16 references

DOI

Abstract

Anti-Remicade antibodies in patients with IBD recognise and functionally inhibit Remsima to a similar degree, suggesting similar immunogenicity and shared immunodominant epitopes on these two infliximab agents. In contrast, anti-adalimumab antibodies do not cross-react with Remsima or Remicade.

References

16

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

Paul Rutgeerts, William J. Sandborn, Brian G. Feagan et al. · New England Journal of Medicine · 2005 · 3.8K citations · Full text

Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

Bruce E. Sands, Frank Anderson, Çharles N. Bernstein et al. · New England Journal of Medicine · 2004 · 2.2K citations · Full text

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

Filip Baert, Maja Noman, Séverine Vermeire et al. · New England Journal of Medicine · 2003 · 2K citations · Full text

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Dae‐Hyun Yoo, Paweł Hrycaj, Pedro C. Miranda et al. · Annals of the Rheumatic Diseases · 2013 · 650 citations · Full text

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease

Stephen B. Hanauer, Carrie Wagner, Mohan Bala et al. · Clinical Gastroenterology and Hepatology · 2004 · 606 citations · Full text

, , +11